

Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated August 31, 2018 (the “**Prospectus**”) issued by Hua Medicine (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “**Qualified Institutional Buyers**” and “**Qualified Purchasers**” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Potential investors of the Offer Shares should note that the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “**Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination**” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, September 14, 2018).

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Friday, October 5, 2018 being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

Global Offering

Number of Offer Shares under the Global Offering	:	104,756,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	5,217,500 Shares (as adjusted after reallocation)
Number of International Offer Shares	:	99,538,500 Shares (as adjusted after reallocation and subject to the Over-allotment Option)
Final Offer Price	:	HK\$8.28 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	:	US\$0.001 per Share
Stock code	:	2552

Joint Sponsors

Goldman Sachs



Joint Global Coordinators and Joint Bookrunners

Goldman Sachs



Joint Lead Managers

Goldman Sachs



**ANNOUNCEMENT OF OFFER PRICE
AND ALLOTMENT RESULTS**

SUMMARY

Applications and Indication of Interest Received

- The Offer Price has been determined at HK\$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%). Based on the Offer Price of HK\$8.28 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$780.6 million (subject to rounding), assuming the Over-allotment Option and the Post-IPO Share Option are not exercised. The Company intends to apply such net proceeds for the following purposes:
 - approximately 39% of the net proceeds, or HK\$304.4 million, will be used for completing the Phase III trials of Dorzagliatin, for both monotherapy and combination trials with metformin;
 - approximately 9% of the net proceeds, or HK\$70.3 million, will be used for further research and development involving Dorzagliatin, which will include combination trials;
 - approximately 27% of the net proceeds, or HK\$210.8 million, will be used for the launch and commercialization of Dorzagliatin in China, including marketing, sales and manufacturing;
 - approximately 11% of the net proceeds, or HK\$85.9 million, will be used for further research on mGLUR5, fixed dose combinations involving Dorzagliatin and personalized diabetes studies;
 - approximately 4% of the net proceeds, or HK\$31.2 million, will be used for exploring additional licensing and partnership opportunities directly relating to diabetes or new therapeutic areas for which we believe there is a significant unmet medical need; and
 - approximately 10% of the net proceeds, or HK\$78.1 million, will be used for our general corporate and working capital purposes.

For details of the use of proceeds, see “Future Plans and Use of Proceeds” in the Prospectus.

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been undersubscribed. The final number of Offer Shares under the Hong Kong Public Offering is 5,217,500 Offer Shares, representing 4.98% of the total number of Offer Shares initially available under the Global Offering. A total of 1,922 valid applications have been received pursuant to the Hong Kong Public Offering on **WHITE** and **YELLOW** Application Forms and through giving **electronic application instructions** to HKSCC via CCASS and under the **HK eIPO White Form** service (www.hkeipo.hk) for a total of 5,217,500 Hong Kong Offer Shares, representing approximately 0.50 times of the total number of 10,476,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- Due to the under-subscription in the Hong Kong Public Offering, the Joint Global Coordinators have exercised their discretion to reallocate unsubscribed Offer Shares under the Hong Kong Public Offering to the International Offering as described in the sub-section headed “Structure of the Global Offering — Reallocation” in the Prospectus. A total number of 5,258,500 Offer Shares initially available for subscription under the Hong Kong Public Offering have been reallocated to the International Offering. As a result of such reallocation, the final number of Shares under the International Offering has been increased to 99,538,500 Offer Shares, representing approximately 95.02% of the total number of Offer Shares in the Global Offering (before any exercise of the Over-allotment Option and the Post-IPO Share Option).

International Offering and the Over-allotment Option

- The Offer Shares initially offered under the International Offering have been moderately over-subscribed. The final number of Offer Shares allocated to the places under the International Offering comprises 99,538,500 Offer Shares, representing 95.02% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option and the Post-IPO Share Option). A total of 100 places have been allotted no more than three board lots of Offer Shares, representing approximately 75.8% of the 132 places under the International Offering, being the total number of places under the International Offering. These places have been allotted 0.12% and 0.10% of the Offer Shares, before over-allocation and post over-allocation respectively, under the International Offering.

- We have applied to the Stock Exchange for, and the Stock Exchange has granted us waivers from strict compliance with Rule 10.04 of the Rules governing the Listing of Securities on the Stock Exchange (the “**Hong Kong Listing Rules**”) and consents under Paragraph 5(2) of Appendix 6 to the Hong Kong Listing Rules (the “**Placing Guidelines**”) to permit the Company to allocate Shares to ABG II-Hua Limited (“**ABG**”), GIC Private Limited (“**GIC**”), BlackRock Asset Management North Asia Limited (“**BAMNA**”) (for and on behalf of BlackRock Health Sciences Trust (“**BHST**”) and BlackRock Health Sciences Opportunities Portfolio, a series of BlackRock Funds (“**BHSO**”, together with BHST, the “**BlackRock Funds**”) and other funds and accounts managed by the investment manager of the BlackRock Funds) and Raymond James & Associate (“**Raymond**”).
- 2,350,000 Offer Shares, 2,350,000 Offer Shares, 10,852,500 Offer Shares and 45,000 Offer Shares, representing approximately 2.24%, 2.24%, 10.36% and 0.04% of the Offer Shares initially available under the Global Offering (before the exercise of the Over-allotment Option and the Post-IPO Share Option), were allocated to ABG, GIC, BAMNA (for and on behalf of the BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds) and Raymond respectively, as placees, each of them being a close associate or affiliate to (i) ABG; (ii) Tetrad Ventures Pte. Ltd.; (iii) BlackRock Funds and (iv) John J. Baldwin, Ann M. Baldwin, Alysia Baldwin Ferro, Tracy Baldwin and John K. Baldwin (“**Baldwin Family**”) respectively.
- 4,176,000 Offer Shares, representing approximately 4.00% of the Offer Shares initially available under the Global Offering (before the exercise of the Over-allotment Option and the Post-IPO Share Option), were allocated to CITIC (to be held on behalf of its clients on a discretionary basis) as a placee. As CITIC and CLSA Limited (“**CLSA**”), one of the joint bookrunners, are both members of the CLSA organization, CITIC is a “connected client” of CLSA within the meaning of paragraph 13(7) of the Placing Guidelines. We have applied to the Hong Kong Stock Exchange for, and the Hong Kong Stock Exchange has granted us, consents under Paragraph 5(1) of the Placing Guidelines to the Hong Kong Listing Rules to permit the Company to allocate Shares in the International Offering to CITIC Securities Company Limited (“**CITIC**”), as a placee, subject to the certain conditions which are described in the section headed “International Offering - Placees Consents under Paragraph 5(1) of the Placing Guidelines” in this announcement.

- Pursuant to the International Underwriting Agreement, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company, and be available on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk. As of the date of this announcement, the Over-allotment Option has not been exercised.
- Save as disclosed above and in the Prospectus, the International Offering is in compliance with the Placing Guidelines. No Offer Shares placed by or through the Joint Global Coordinators and the Underwriters under the Global Offering have been placed with any core connected person (as such term is defined in the Hong Kong Listing Rules) of the Company or, save as disclosed in the foregoing to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees. The Directors confirm that no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering.

Results of Allocations

- The final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on or before Thursday, September 13, 2018 in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese) and on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk.

- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering, including applications made under **WHITE** and **YELLOW** Application Forms and by giving **electronic application instructions** to HKSCC or through the designated **HK eIPO White Form** service, which will include the Hong Kong identity card numbers, passport numbers or Hong Kong business registration numbers of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:
 - in the announcement to be posted on the Stock Exchange’s website at www.hkexnews.hk and on the Company’s website at www.huamedicine.com by no later than 9:00 a.m. on Thursday, September 13, 2018;
 - from the designated results of allocation website at www.tricor.com.hk/ipo/result with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Thursday, September 13, 2018 to 12:00 midnight on Wednesday, September 19, 2018;
 - by telephone enquiry line by calling 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, September 13, 2018 to Tuesday, September 18, 2018 on a business day; and
 - in the special allocation results booklets which will be available for inspection during the opening hours from Thursday, September 13, 2018 to Monday, September 17, 2018 at all the designated branches of the receiving banks at the addresses set out in the paragraph headed “Results of allocation” below.

Despatch/Collection of Share Certificates and Refund Monies

- Applicants who have applied for 1,000,000 Hong Kong Offer Shares or more and are successfully allocated Hong Kong Offer Shares and have provided all information required by their **WHITE** Application Forms, and applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service by submitting electronic applications through the designated website www.hkeipo.hk and whose applications are wholly successful, may collect their share certificate(s) (where applicable) in person from Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, September 13, 2018 or such other date as notified by the Company in the newspapers.

- Share certificates for Hong Kong Offer Shares allotted to applicants using **WHITE** Application Forms or **HK eIPO White Form** service, which are either not available for personal collection, or which are available but are not collected in person within the time specified for collection, are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on Thursday, September 13, 2018.
- Wholly successful applicants using **YELLOW** Application Forms or by giving **electronic application instructions** to HKSCC will have their share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant as instructed by the applicants in the **YELLOW** Application Forms or any designated CCASS Participants giving **electronic application instructions** on their behalf on Thursday, September 13, 2018.
- Applicants applying through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants using **WHITE** or **YELLOW** Application Forms who have applied for 1,000,000 Hong Kong Offer Shares or more and have provided all information required by their **WHITE** or **YELLOW** Application Forms may collect their refund cheque(s) (where applicable) from Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, September 13, 2018 or such other date as notified by the Company in the newspapers.
- Refund cheque(s) for wholly successful applicants using **WHITE** or **YELLOW** Application Forms, which are either not available for personal collection or which are available but are not collected in person, are expected to be despatched by ordinary post to those entitled at their own risk on Thursday, September 13, 2018. No interest will be paid thereon.
- For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through a single bank account, refund monies (if any) will be despatched to their application payment bank account in the form of e-Auto Refund payment instructions. For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through multiple bank accounts, refund monies (if any) will be despatched to the addresses specified on the **HK eIPO White Form** applications in the form of refund cheque(s) by ordinary post and at their own risk.

- Refund monies (if any) for applicants giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker or custodian on Thursday, September 13, 2018.

Public Float

- The Directors of the Company confirm that the market capitalization of the number of Shares to be held by the public will satisfy the minimum requirement prescribed under Rule 18A.07 of the Listing Rules that a portion of the total number of the Shares with a market capitalisation of at least HK\$375 million are held by the public at the time of the Listing. The Directors of the Company confirm that the three largest public shareholders of the Company do not hold more than 50% of the Shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules. The Directors of the Company confirm that there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

Commencement of Dealings

- Share certificates issued in respect of the Hong Kong Offer Shares will only become valid certificates of title at 8:00 a.m. on Friday, September 14, 2018 provided that the Global Offering has become unconditional in all respects and the right of termination as described in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for termination" in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Hong Kong Offer Shares. No receipt will be issued for application monies received.
- Dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Friday, September 14, 2018. The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 2552.

Investor should be aware that the concentration of the Shareholders may affect the liquidity of the Shares. Consequently, Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

APPLICATIONS AND INDICATION OF INTEREST RECEIVED

The Offer Price has been determined at HK\$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%). Based on the Offer Price of HK\$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$780.6 million, assuming the Over-Allotment Option and the Post-IPO Share Option are not exercised. The Company intends to apply such net proceeds in accordance with the purposes set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

The Company announces that at the close of the application lists at 12:00 noon on Wednesday, September 5, 2018, a total of 1,922 valid applications pursuant to the Hong Kong Public Offering on **WHITE** and **YELLOW** Application Forms and through giving **electronic application instructions** to HKSCC via CCASS and under the **HK eIPO White Form** service (www.hkeipo.hk) for a total of 5,217,500 Hong Kong Offer Shares were received, representing approximately 0.50 times of the total number of 10,476,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.

- 1,921 valid applications for a total of 4,217,500 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$9.28 per Offer Share (the Offer Price excludes brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) of HK\$5 million or less, representing approximately 0.81 times of 5,238,000 Hong Kong Offer Shares initially comprised in Pool A; and
- One valid application for 1,000,000 Hong Kong Offer Shares was for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$9.28 per Offer Share (the Offer Price excludes brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) of more than HK\$5 million, representing 0.19 times of 5,238,000 Hong Kong Offer Shares initially comprised in Pool B.

Applications not completed in accordance with the instructions set out in the Application Forms have been rejected. No multiple applications or suspected multiple applications have been identified and rejected. One application has been rejected due to bounced cheques. No application has been rejected due to invalid applications. No application for more than 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering (that is, more than 5,238,000 Hong Kong Offer Shares) has been identified.

Due to the under-subscription in the Hong Kong Public Offering, the Joint Global Coordinators have exercised their discretion to reallocate unsubscribed Offer Shares under the Hong Kong Public Offering to the International Offering as described in the sub-section headed “Structure of the Global Offering — Reallocation” in the Prospectus. A total number of 5,258,500 Offer Shares initially available for subscription under the Hong Kong Public Offering have been reallocated to the International Offering. As a result of such reallocation, the final number of Shares under the International Offering has been increased to 99,538,500 Offer Shares, representing approximately 95.02% of the total number of Offer Shares in the Global Offering (before any exercise of the Over-allotment Option and the Post-IPO Share Option).

INTERNATIONAL OFFERING

The Company further announces that the Offer Shares initially offered under the International Offering have been moderately over-subscribed. The final number of Offer Shares allocated to the placees under the International Offering comprises 99,538,500 Offer Shares, representing 95.02% of the total number of Offer Shares initially available under the Global Offering (before the exercise of the Over-allotment Option and the Post-IPO Share Option). A total of 100 placees have been allotted no more than three board lots of Offer Shares, representing approximately 75.8% of the 132 placees under the International Offering, being the total number of placees under the International Offering. These placees have been allotted 0.12% and 0.10% of the Offer Shares, before over-allocation and post over-allocation respectively, under the International Offering.

Placees with Consents under Paragraph 5(1) of the Placing Guidelines

We have applied to the Stock Exchange for, and the Stock Exchange has granted us a consent under paragraph 5(1) of the Placing Guidelines for allocation to CITIC Securities Company Limited (“CITIC”), and the relevant allocations of Shares are in compliance with all the conditions under the consent granted by the Stock Exchange.

4,176,000 Offer Shares, representing approximately 4.00% of the Offer Shares initially available under the Global Offering (before the exercise of the Over-allotment Option and the Post-IPO Share Option), were allocated to CITIC (to be held on behalf of its clients on a discretionary basis) as a placee. As CITIC and CLSA Limited (“CLSA”), one of the joint bookrunners, are both members of the CLSA organization, CITIC is a “connected client” of CLSA within the meaning of paragraph 13(7) of the Placing Guidelines. We have applied to the Stock Exchange for a consent under Paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to CITIC (to be held on behalf of its clients on a discretionary basis).

On the basis that (A) the Offer Shares to be subscribed by, and placed to, CITIC will be held by CITIC on behalf of independent third parties; (B) the Company and CLSA have confirmed, and the Joint Bookrunners have confirmed to the best of their knowledge and belief, that CLSA has not participated, and will not participate, in the decision making process or relevant decisions among the Company, the Joint Bookrunners and the underwriters as to whether CITIC will be selected as a placee; (C) the Company and CLSA have confirmed, and the Joint Bookrunners have confirmed, to the best of their knowledge and belief, that no preferential treatment has been, nor will be, given to CITIC by virtue of its relationship with CLSA in any allocation in the placing tranche, and details of the allocation will be disclosed in this allotment results announcement; (D) CITIC has confirmed that, to the best of its knowledge and belief, it has not received and will not receive any preferential treatment in the allocation under the Global Offering as a placee by virtue of its relationship with CLSA; and (E) each of the Joint Sponsors has confirmed that, based on (i) the discussions with the Company, CLSA as the connected distributor and the Joint Bookrunners; and (ii) the confirmations provided to the Stock Exchange by the Company, CLSA, the Joint Bookrunners and CITIC, and to the best of the knowledge and belief of the Joint Sponsors, they have no reason to believe that CITIC received any preferential treatment in the allocation under the Global Offering as a placee by virtue of its relationship with CLSA, the Stock Exchange has granted us a consent under Paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to CITIC on a discretionary basis.

Save as disclosed above, to the best knowledge of the Directors, CITIC is an independent third party, is not our connected person or existing shareholder, is not a close associate of any of our existing shareholders, and is independent from our connected persons and their respective close associates.

Placees with Waivers under Rule 10.04 of the Hong Kong Listing Rules and Consents under Paragraph 5(2) of the Placing Guidelines

Certain Offer Shares were placed to close associates or affiliate of certain existing indirect or direct shareholders of the Company, details of which are set out below:

Placee	Number of Offer Shares placed	Approximate % of the Offer Shares*	Approximate % of the total issued share capital following the completion of the Global Offering*	Relationship with the existing shareholder of the Company
ABG II-Hua Limited (“ABG”)	2,350,000 (“ABG Placement”)	2.24	3.66	ABG is an existing shareholder
GIC Private Limited (“GIC”)	2,350,000 (“GIC Placement”)	2.24	3.07	The existing shareholder, Tetrad Ventures Pte. Ltd. is a limited company established and managed by GIC Special Investments Pte. Ltd., which is wholly-owned by GIC
BlackRock Asset Management North Asia Limited (“BAMNA”) ⁽²⁾	10,852,500 (“Placement”)	10.36	1.77	BlackRock Funds are existing shareholders and BAMNA is an affiliate of the BlackRock Funds
Raymond James & Associate (“Raymond”)	45,000 (“Raymond Placement”)	0.04	2.59	John J. Baldwin is a client of Raymond James & Associates Inc, which is a non-discretionary fund holding investment on behalf of John J. Baldwin and John J. Baldwin makes the ultimate investment decisions. John J. Baldwin, Ann M. Baldwin, Alysia Baldwin Ferro, Tracy Baldwin and John K. Baldwin are within the same family (“Baldwin Family”) and are existing shareholders

- (1) Assuming that the Over-allotment Option and the Post-IPO Share Option are not exercised.
- (2) BAMNA participates as placee for and on behalf of the BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds.

On the basis of (i) the confirmations as described below; (ii) all of abovementioned existing shareholders of the Company is interested in less than 5% of the Company’s shareholding interest before the Listing; (iii) none of ABG, GIC, BAMNA (for and on behalf of BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds) and Raymond is a core connected person of the Company or its close associate under the Listing Rules; (iv) the allocation to ABG, GIC, BAMNA (for and on behalf of BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds) and Raymond will not affect the Company’s ability to satisfy the public float requirements under Rules 8.08 and 18A.07 of the Listing Rules (v) the abovementioned existing shareholders of the Company will not have any special

rights with regard to the Company surviving the Listing, we have applied to the Stock Exchange for, and the Stock Exchange has granted us a waiver from Rule 10.04 of the Hong Kong Listing Rules and a consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate Shares to each of ABG, GIC, BAMNA (for and on behalf of the BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds and Raymond, and the relevant allocations of Shares are in compliance with all the conditions under the consent granted by the Stock Exchange.

In respect of the ABG Placement, GIC Placement, BAMNA Placement and Raymond Placement, (A) each of ABG, GIC, BAMNA and Raymond has confirmed to the Company, the Joint Sponsors and the Joint Bookrunners that (i) they are not connected persons of the Company (as defined in the Listing Rules) and are not accustomed to take instructions from a connected person in relation to the acquisition, disposal, voting or other disposition of Shares held or to be allotted to them; (ii) they are not persons who will become connected persons of the Company immediately upon completion of the Global Offering; and (iii) their subscription for Shares is not being financed by or being made on instruction of any of the connected persons of the Company; (B) Company has confirmed that no preferential treatment has been, nor will be, given to each of ABG, GIC, BAMNA and Raymond or their close associates by virtue of their relationship with the Company in the allocation process under the placing tranche, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement; and (C) the Joint Bookrunners has confirmed, to the best of their knowledge and belief, that no preferential treatment has been, nor will be, given to each of ABG, GIC, BAMNA and Raymond or their close associates by virtue of their relationship with the Company in any allocation in the allocation process under the placing tranche, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement. Based on (a) the foregoing Company's and Joint Bookrunners' confirmations and (b) the Joint Sponsors discussion with the Company and the Joint Bookrunners, and to the best of our knowledge and belief, the Joint Sponsors have no reasons to believe that ABG, GIC, BAMNA and Raymond or any of their close associates received or will receive any preferential treatment in the IPO allocation as a placee by virtue of its relationship with the Company, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement.

Pursuant to the International Underwriting Agreement, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company, and be available on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk. As of the date of this announcement, the Over-allotment Option has not been exercised.

Save as disclosed above, to the best knowledge of the Directors, no Offer Shares under the International Offering have been allocated to applicants who are core connected persons of the Company, Directors, existing Shareholders or their respective close associates within the meaning of the Hong Kong Listing Rules.

Save as disclosed above, the International Offering is in compliance with the Placing Guidelines. No Offer Shares placed by or through the Joint Global Coordinators and the Underwriters under the Global Offering have been placed with any core connected person (as such term is defined in the Hong Kong Listing Rules) of the Company or, save as disclosed in the foregoing to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the paragraph headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus, valid applications made by the public on **WHITE** and **YELLOW** Application Forms and through giving **electronic application instructions** to HKSCC via CCASS and to the **HK eIPO White Form** Service Provider under the **HK eIPO White Form** service will be conditionally allocated on the basis set out below:

Number of Hong Kong Offer Shares applied for	Number of valid applications	Basis of allotment/ballot	Percentage allotted of the total number of Hong Kong Offer Shares applied for
POOL A			
500	1,420	500 shares	100%
1,000	210	1,000 shares	100%
1,500	45	1,500 shares	100%
2,000	53	2,000 shares	100%
2,500	26	2,500 shares	100%
3,000	25	3,000 shares	100%
3,500	7	3,500 shares	100%
4,000	13	4,000 shares	100%
4,500	5	4,500 shares	100%
5,000	46	5,000 shares	100%
10,000	27	10,000 shares	100%
15,000	7	15,000 shares	100%
20,000	11	20,000 shares	100%
40,000	11	40,000 shares	100%
60,000	6	60,000 shares	100%
80,000	2	80,000 shares	100%
100,000	4	100,000 shares	100%
200,000	2	200,000 shares	100%
300,000	1	300,000 shares	100%
	<u>1,921</u>		

Number of Hong Kong Offer Shares applied for	Number of valid applications	Basis of allotment/ballot	Percentage allotted of the total number of Hong Kong Offer Shares applied for
POOL B			
1,000,000	<u>1</u>	1,000,000	100%

The final number of Offer Shares comprised in the Hong Kong Public Offering is 5,217,500 Offer Shares, representing 4.98% of the total number of the Offer Shares initially available under the Global Offering.

RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering, including applications made under **WHITE** and **YELLOW** Application Forms and by giving **electronic application instructions** to HKSCC or through the designated **HK eIPO White Form** service, which will include the Hong Kong identity card numbers, passport numbers or Hong Kong business registration numbers of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:

- in the announcement to be posted on the Stock Exchange’s website at www.hkexnews.hk and on the Company’s website at www.huamedicine.com by no later than 9:00 a.m. on Thursday, September 13, 2018;
- from the designated results of allocation website at www.tricor.com.hk/ipo/result with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Thursday, September 13, 2018 to 12:00 midnight on Wednesday, September 19, 2018;
- by telephone enquiry line by calling 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, September 13, 2018 to Tuesday, September 18, 2018 on a business day; and
- in the special allocation results booklets which will be available for inspection during the opening hours from Thursday, September 13, 2018 to Monday, September 17, 2018 at all the receiving banks designated branches at the addresses set out below.

Wing Lung Bank Limited

	Branch Name	Address
Hong Kong Island	Head Office	45 Des Voeux Road Central
	Johnston Road Branch	118 Johnston Road
	Kennedy Town Branch	28 Catchick Street
Kowloon	Mong Kok Branch	Basement, Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
New Territories	Tsuen Wan Branch	251 Sha Tsui Road

The final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on or before Thursday, September 13, 2018 in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese) and on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk.

SHAREHOLDING CONCENTRATION ANALYSIS

We set out below a summary of allotment results under the International Offering without taking into account any exercise of Post-IPO Share Option:

- subscription and number of Shares held by the top 1, 5, 10 and 25 of the placees out of the International Offering, total Offer Shares and total issued share capital of the Company upon Listing:

Placee	Subscription	Number of Shares held upon Listing	Subscription as	Subscription as	Subscription as	% of Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
			% of International Offering (assuming no exercise of the Over-allotment Option)	% of International Offering (assuming the Over-allotment Option is exercised in full)				
Top 1	18,500,000	18,500,000	18.59%	16.05%	17.66%	15.36%	1.76%	1.73%
Top 5	61,003,500	61,003,500	61.29%	52.93%	58.23%	50.64%	5.80%	5.71%
Top 10	87,603,500	87,603,500	88.01%	76.01%	83.63%	72.72%	8.33%	8.21%
Top 20	111,359,500	111,359,500	111.88%	96.62%	106.30%	92.44%	10.59%	10.43%
Top 25	114,198,500	114,198,500	114.73%	99.09%	109.01%	94.79%	10.86%	10.70%

- subscription and number of Shares held by the top 1, 5, 10 and 25 of the Shareholders out of the International Offering, total Offer Shares and total issued share capital of the Company upon Listing:

Shareholder	Subscription	Number of Shares held upon Listing	Subscription as	Subscription as	Subscription as	% of Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issue share capital upon Listing (assuming the Over-allotment Option is exercised in full)	% of total issue share capital upon Listing (assuming the Over-allotment Option is exercised in full)
			% of International Offering (assuming no exercise of the Over-allotment Option)	% of International Offering (assuming the Over-allotment Option is exercised in full)				
Top 1	—	125,088,960	—	—	—	—	11.89%	11.72%
Top 5	—	485,260,050	—	—	—	—	46.13%	45.45%
Top 10	2,350,000	708,503,215	2.36%	2.04%	2.24%	1.95%	67.35%	66.36%
Top 20	48,688,500	935,322,090	48.91%	42.25%	46.48%	40.42%	88.92%	87.61%
Top 25	72,848,500	974,828,830	73.19%	63.21%	69.54%	60.47%	92.67%	91.31%

Results of Applications Made by WHITE Application Forms or HK eIPO White Form

The followings are the identification document numbers (where supplied) of wholly or partially successful applicants using **WHITE** Application Forms or **HK eIPO White Form** and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their identification document numbers are not shown.

以白色申請表格或網上白表提出申請的配發結果

以下為使用白色申請表格或網上白表提出申請而全部或部分獲接納的申請人的身份證明文件號碼(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼，其結果將不會顯示。

Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目
A9230729	500						
C6045764	500						
D4605005	500						
E5497063	15,000						
E7137587	1,500						
G1355995	1,000						
G255794A	500						
G3704431	500						
K0438049	500						
K0503029	500						
K4911431	1,500						
K8746230	500						
P2401383	5,000						
P5739881	500						
P8207295	500						

Results of Applications Made by YELLOW Application Forms (Through Designated CCASS Clearing/Custodian Participants)

The followings are the identification document numbers (where supplied) of wholly or partially successful applicants using YELLOW Application Forms through designated CCASS Clearing/Custodian Participants and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their identification document numbers are not shown.

以黃色申請表格提出申請的配發結果 (透過指定中央結算系統結算/託管商參與者)

以下為使用黃色申請表格透過指定中央結算系統結算/託管商參與者提出申請而全部或部分獲接納的申請人的身份證明文件號碼(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼，其結果將不會顯示。

Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目
A3596403	1,000						
D2308526	500						
R4239813	2,500						

Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS

The followings are the identification document numbers (where supplied) of wholly or partially successful applicants made by giving **Electronic Application Instructions** to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their identification document numbers are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部分獲接納的申請人的身份證明文件號碼(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼,其結果將不會顯示。

Identification document number(s)	No. of Shares allotted	Identification document number(s)	No. of Shares allotted	Identification document number(s)	No. of Shares allotted	Identification document number(s)	No. of Shares allotted
身份證明文件號碼	獲配發股份數目	身份證明文件號碼	獲配發股份數目	身份證明文件號碼	獲配發股份數目	身份證明文件號碼	獲配發股份數目
0003314	5,000	06051823	500	111170032	500	308013272	500
0008226	3,500	06053544	500	11123822	500	308060214	500
001150011	500	06113710	500	11150014	1,500	308085421	500
001205917	5,000	06213934	500	112091800	100,000	308233054	500
001239010	2,000	06233010	1,000	11230015	500	308258151	500
0012443	60,000	06236202	500	11230822	500	309093275	500
001284613	500	06251618	500	112319087	500	309245252	1,500
0019581	500	06284933	500	112322600	1,000	310041510	4,500
002160950	1,000	07070031	500	112403400	1,000	310202422	500
002231640	500	0711151X	500	11270599	500	311263811	500
002270012	1,500	07140444	500	11274913	500	31225771X	500
004070619	500	07152138	500	12024218	500	312295310	500
004286218	500	07163911	500	12104016	500	31404817	1,000
005200987	500	0718401X	2,500	12134928	500	32010219	1,000
005251712	500	07211014	500	12165571	500	32010619	500
005290072	500	07280728	500	12174037	500	32011319	1,000
00529441X	500	08010035	500	12301216	500	32028219	500
006124828	500	08016356	500	128606	1,000	32052019	1,000
008103236	500	08040814	500	130604197	500	32072119	1,000
009082938	2,500	08093439	1,000	13063619	1,000	320981199	500
009103348	500	08113621	500	13063619	1,000	33030219	20,000
009491000	4,000	08140057	500	14272319	1,000	33032619	1,000
01006144X	3,000	08144936	500	201130036	500	33032719	20,000
010090613	1,000	0817191X	500	201172167	500	33252819	500
01024031	500	08282322	500	202047059	500	34010419	500
01072225	500	0842608	1,500	202061215	500	34213019	500
01082918	500	0842695	1,500	203043038	500	35012719	1,000
011040011	1,000	0863195	1,000	203250022	500	35012719	10,000
01131422	500	0902377X	1,000	20328132X	500	35020419	10,000
01170619	500	09024910	500	203294979	500	35020419	10,000
012212217	500	09030816	500	204013618	500	350425196	500
01226121X	500	09053044	500	204053210	1,000	350425196	500
01247714	500	09075371	500	204091634	500	350425199	500
0145570	1,500	09100313	500	205012516	2,500	350425199	500
02012312	500	09131631	500	20505044X	500	350583197	2,000
02064021	500	09140318	500	205091055	500	350823198	500
02064529	500	09184345	500	205181718	500	35260119	20,000
02153214	500	09240145	500	205231631	500	357187970	5,000
02192822	500	09256345	500	206085015	500	359764495	500
02212019	500	10040316	500	206261625	500	360122198	500
0221303X	500	10040445	500	207122738	500	36042819	1,000
025520001	5,000	10073014	500	207152013	500	36213619	500
0286985	1,500	10100013	500	20818001X	500	36213619	500
03034710	500	10100621	500	208184408	500	36213619	500
03057992	500	10100894	500	208264817	500	370421196	1,000
03092459	1,000	10102182X	500	209010065	500	370523198	500
03126066	500	10104003X	1,500	209121917	500	371323817	500
03174931	500	101167135	500	209166073	5,000	374101277	5,000
03220933	500	101172518	3,000	209202334	500	381024744	80,000
03240059	500	1015231X	500	211034517	2,500	394045355	2,000
03275749	500	10165317	500	211115526	500	40112901X	1,000
03300710	500	102062123	500	211129730	5,000	401277219	500
0397179	1,000	10256515	500	212037036	500	404254616	1,500
04012510	500	103283247	500	212100030	1,500	404282714	500
04020956	500	104033816	500	212182419	1,000	405222014	500
04060170	500	105052253	500	220721199	500	405250322	500
04085213	500	105094184	500	229005197	500	405291012	500
04085535	500	105111227	500	230404198	500	406250911	1,000
04137316	500	105283019	500	236545851	500	407100031	500
04200015	500	106203518	3,000	292654L	500	408162372	500
04231049	500	107043259	500	296506C	2,000	408210612	500
04284666	500	107130827	500	301032016	500	408244050	500
05014034	500	107254364	500	303296678	500	410126049	5,000
05100416	500	108135424	500	303301814	500	410230970	1,000
05113022	500	108257712	1,500	304165514	500	410291218	500
05132039	500	11023817	500	304180629	500	411013640	500
05266450	500	11025838	500	304270253	500	411071330	500
05291623	500	11065149	500	304280824	500	41152819	1,000
0529441X	500	111034076	500	306154916	500	412200914	500
06015548	500	111096820	500	307032065	500	412211240	500
06039012	500	111123822	500	307140444	500	420114199	500

Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS

The followings are the identification document numbers (where supplied) of wholly or partially successful applicants made by giving **Electronic Application Instructions** to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their identification document numbers are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部分獲接納的申請人的身份證明文件號碼(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼,其結果將不會顯示。

Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目
42052119	1,000	606205552	500	812093217	500	D3775020	500
420802198	1,500	607103633	1,000	9004E17	500	D381882A	1,000
42108319	500	609141023	500	90103245X	1,500	D4083548	500
42220219	500	60921001X	500	901042814	1,500	D4512643	4,000
42900119	500	610111036	1,000	901274018	1,000	D456448-1	500
42900419	500	610111197	1,000	902060311	500	D4772890	500
42900419	500	610120028	500	902170216	500	D4825196	500
42900419	500	610260649	500	903100020	500	D5655081	1,500
42900419	500	610291832	500	903236255	500	D5711402	60,000
43010319	1,000	611011414	1,000	903284114	500	D5917949	1,000
430403196	2,500	611185833	500	90523072X	500	D6288309	500
430621196	500	61122001X	500	905274717	500	D6732713	500
44010419	20,000	620421197	1,500	906012274	1,000	D7042176	500
44010519	40,000	622626198	10,000	906050015	3,000	D7052457	500
44030119	1,000	69530006	2,000	907040328	500	D807621A	4,000
44030119	5,000	701100030	500	907154413	500	D8283215	500
440301198	10,000	702012510	500	907181631	500	D8542903	1,000
44050319	500	70210051X	500	907195045	1,000	D858582	2,000
44078319	1,000	702183617	500	908140235	500	E00155279	500
441202197	10,000	70318325X	1,000	909040022	500	E05905905	500
44128319	500	703201249	500	909043010	1,000	E12037554	500
44132419	500	704014612	500	909141834	500	E12468499	500
44142519	500	704029774	500	909222818	1,000	E12488598	500
44162319	1,000	705146333	500	910052817	500	E12514566	500
44188119	500	708190539	1,500	910100894	500	E12529790	500
44282719	500	708303753	2,000	910191034	500	E20227555	500
44532319	500	70908703X	500	910220792	500	E22142087	500
44532319	500	709130021	500	910250023	500	E22159290	500
44532319	500	711161172	2,000	91025240X	500	E22338153	500
44532319	500	711277048	2,500	910293872	500	E22375260	500
44532319	500	712100036	500	91103481X	500	E22434353	500
44532319	1,000	712130818	500	911040620	500	E2252892	500
450204198	500	712130933	1,000	911131815	500	E44775502	1,000
501262717	500	754012854	3,000	911160537	500	E5149693	500
503235017	1,000	762074961	500	911184517	500	E5477151	40,000
504254414	500	797169141	1,000	912173213	500	E5947859	1,000
505110035	10,000	800126C	1,500	912315734	500	E6182376	500
505136715	500	801194031	500	9597149	3,000	E7483493	1,000
505181216	500	802022757	500	A0580115	500	E7700109	500
506100319	500	803062261	500	A10147134	500	E7891567	1,000
506127429	500	803101716	500	A1663472	500	E8330291	1,000
507230036	500	80315011X	500	A1663480	500	E8442995	500
508070418	500	803240530	500	A22252637	500	E88922696	500
508076469	500	803249029	500	A38215615	15,000	E8956115	500
508181832	500	803261827	500	A6630424	1,000	E9049383	500
508235739	500	803296328	500	A817826A	500	E9056878	1,000
508251841	500	804080033	5,000	A8339263	500	E9382732	500
509080025	500	804080749	500	A9839820	500	E943421A	500
509261629	500	804205126	500	B12208038	500	E9521791	500
51004581X	500	804260812	500	B12266639	500	E9854405	500
510068515	500	805188010	1,000	C04949461	500	EB6916178	2,500
510100013	500	806053544	500	C3287856	1,000	G003219A	1,000
51022719	1,000	806172020	500	C3591237	1,000	G0848769	1,000
511023197	5,000	80704202X	500	C42570073	5,000	G085887A	500
511157312	500	807181411	500	C4552847	500	G1633200	500
511242027	1,000	807260013	1,500	C470256	500	G1963235	40,000
512060218	1,500	808100154	1,500	C48079031	500	G210693A	500
512193215	500	808170231	500	C491367A	500	G2285222	1,000
51231102X	500	809178149	500	C65287591	2,500	G25610221	500
60104561X	2,500	809273317	500	C6595780	500	G3530484	500
601310215	500	809298238	500	C77688590	1,000	G3613975	500
602023024	2,500	810010623	1,000	D0343006	500	G3825603	1,000
602082730	500	810070130	1,000	D0844579	500	G390964-5	500
602140715	500	810100075	2,500	D1034635	500	G406780A	500
602222717	500	810209416	2,000	D1429451	500	G4124110	1,000
602271331	500	810595200	3,000	D226913A	1,000	G4299506	500
603057992	500	811032917	500	D2373654	1,000	G4352032	500
603112136	10,000	811110921	500	D2882028	20,000	G44120415	100,000
603140422	5,000	811174050	500	D3165435	500	G4538659	5,000
604080713	500	81122169X	3,000	D3329691	1,000	G4538667	5,000
605063635	1,000	811301514	500	D3693660	1,000	G47638653	500

Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS

The followings are the identification document numbers (where supplied) of wholly or partially successful applicants made by giving **Electronic Application Instructions** to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their identification document numbers are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部分獲接納的申請人的身份證明文件號碼(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼，其結果將不會顯示。

Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目	Identification document number(s) 身份證明文件號碼	No. of Shares allotted 獲配發股份數目
G49742169	1,000	IS9967852	500	Q22346715	500	Y6494437	1,000
G5444976	2,000	J22025890	500	R0441979	500	Z0297683	500
G5849461	1,000	K017674-5	500	R12457029	500	Z052552A	500
G6053164	5,000	K0204145	1,000	R150089	500	Z099872A	500
G6330311	1,000	K1025538	500	R1585346	500	Z1123379	500
G6556824	500	K1141171	500	R2730803	500	Z1733878	500
G8035708	1,000	K1551833	500	R3500143	500	Z2175623	1,000
GS037201B	2,500	K1693522	500	R3573469	3,000	Z2566916	1,000
GS057632B	10,000	K1896180	1,000	R3700940	1,000	Z2834155	80,000
GS076993B	500	K192291-2	500	R3703095	500	Z3123376	500
GS090903B	2,500	K2117819	500	R4028413	500	Z325054-8	500
GS108962B	10,000	K2120550	500	R4080628	500	Z3412696	500
GS112897B	500	K2633876	500	R4081268	20,000	Z3425887	1,000
GS130209B	2,000	K2807955	1,000	R4372211	500	Z3474446	500
GS137513B	500	K297049A	2,000	R4461362	500	Z3576621	500
GS137979B	500	K297503-3	500	R4496255	500	Z3772773	500
GS139073B	4,500	K3010724	1,000	R4627341	1,000	Z4023901	500
GS139635B	60,000	K3605248	1,000	R4783955	500	Z4112807	500
GS151912B	1,000	K4357116	500	R5998785	500	Z4390467	20,000
H060040	500	K454078-6	500	R7072685	10,000	Z4497660	500
H364258 (7	500	K5094240	500	R7383508	500	Z4618832	500
H4198559	500	K535064-6	500	R765742A	500	Z4731965	500
H4330724	1,000	K5629659	500	R8373050	1,000	Z5545677	4,000
H4330732	1,000	K7089562	500	R8398649	3,500	Z629309-4	500
H4886722	500	K7254946	500	S12340869	500	Z6363386	1,000
I20025476	500	K737959-5	500	S22357349	500	Z6814159	500
IS1031673	500	K7468857	60,000	S22446905	500	Z6854495	1,000
IS1055443	500	K7642482	500	T12024617	500	Z7059729	5,000
IS1189181	5,000	K7990499	2,500	T12061971	500	Z731495	500
IS1464429	500	K8637725	500	T12155513	500	Z7463147	500
IS1481473	500	K8810796	500	T12349849	500	Z850942	500
IS1493174	500	K9276262	4,000	T22024626	500	Z867849A	500
IS1599728	500	K9287019	1,000	T22103946	500	Z8857238	1,000
IS2118417	500	M007394	500	T22306533	500	Z9668633	500
IS2369126	500	M0230613	1,000	V0107611	500	Z9827340	500
IS2429533	500	M3929189	500	V0569046	500		
IS3080284	500	M4037427	500	V0635960	60,000		
IS3082257	500	M6323168	500	V0838152	500		
IS3521622	500	M761400A	500	V083825A	500		
IS3605706	500	OS185586	500	V0838268	500		
IS3634896	500	OS188056	500	V0844403	1,000		
IS3863528	500	OS188141	500	V0849707	500		
IS4368511	500	OS188146	500	V1238272	4,000		
IS4413200	500	OS188148	500	V71265755	2,500		
IS4446863	500	OS188156	500	Y013116-2	500		
IS5168305	500	OS188159	500	Y0181798	1,000		
IS5466411	500	OS188160	500	Y020871	500		
IS5472119	500	OS380067	1,500	Y0236541	500		
IS5560611	500	OS780002	500	Y0400996	500		
IS5602492	500	P0568701	500	Y0622069	500		
IS5650824	500	P0644564	500	Y075173A	500		
IS5675329	500	P065897	500	Y0970776	500		
IS5719337	500	P0839918	500	Y113192	500		
IS5755752	500	P12416879	500	Y115901A	500		
IS6539026	500	P1739526	500	Y1221610	500		
IS6591449	500	P2021815	500	Y1636942	500		
IS6754741	500	P2038378	500	Y1645224	500		
IS6775243	500	P3010213	500	Y184109	500		
IS6796398	500	P3301617	500	Y208126A	1,000		
IS6911202	1,500	P3456173	500	Y2082983	500		
IS7463685	500	P488201	500	Y2371950	500		
IS7516835	500	P5637515	500	Y2515251	500		
IS7520629	15,000	P6095856	500	Y2744528	3,000		
IS7857497	500	P6382294	500	Y3484651	500		
IS7859100	500	P6931549	2,500	Y3486670	500		
IS8055791	500	P7491283	500	Y4084037	500		
IS8169980	500	P7502838	500	Y439967	500		
IS8321016	500	P7819424	1,000	Y5366915	1,000		
IS8399427	500	P8189165	500	Y5533838	1,000		
IS8672554	500	P9158409	1,000	Y574202A	500		
IS9277549	500	P9888989	500	Y6228745	500		

DESPATCH/COLLECTION OF SHARE CERTIFICATES AND REFUND CHEQUES

Applicants who have applied for 1,000,000 Hong Kong Offer Shares or more and are successfully allocated Hong Kong Offer Shares and have provided all information required by their **WHITE** Application Forms, and applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service by submitting electronic applications through the designated website www.hkeipo.hk and whose applications are wholly successful, may collect their share certificate(s) (where applicable) in person from Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, September 13, 2018 or such other date as notified by the Company in the newspapers.

Applicants being individuals who are eligible for personal collection cannot authorize any other person to make the collection on their behalf. Corporate applicants which opt for personal collection must attend by their authorized representatives bearing letters of authorization from their corporations stamped with the corporations' chops. Both individuals and authorized representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Tricor Investor Services Limited.

Share certificates for Hong Kong Offer Shares allotted to applicants using **WHITE** Application Forms or **HK eIPO White Form** service, which are either not available for personal collection, or which are available but are not collected in person within the time specified for collection, are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on Thursday, September 13, 2018.

Wholly successful applicants using **YELLOW** Application Forms or by giving **electronic application instructions** to HKSCC will have their share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant as instructed by the applicants in the **YELLOW** Application Forms or any designated CCASS Participants giving **electronic application instructions** on their behalf on Thursday, September 13, 2018.

Applicants applying through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.

Applicants applying as a CCASS Investor Participant on **YELLOW** Application Forms or by giving **electronic application instructions** to HKSCC via CCASS should check the announcement made by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Thursday, September 13, 2018 or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants applying as a CCASS Investor Participant on **YELLOW** Application Forms or by giving **electronic application instructions** to HKSCC via CCASS may also check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies (if any) payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time) immediately after the credit of the Hong Kong Offer Shares to the CCASS Investor Participant stock accounts. HKSCC will also make available to the CCASS Investor Participants an activity statement showing the number of Hong Kong Offer Shares credited to their CCASS Investor Participant stock accounts and (for CCASS Investor Participants applying by giving **electronic application instructions** to HKSCC) the refund amount credited to their respective designated bank accounts (if any).

Applicants using **WHITE** or **YELLOW** Application Forms who have applied for 1,000,000 Hong Kong Offer Shares or more and have provided all information required by their **WHITE** or **YELLOW** Application Forms may collect their refund cheque(s) (where applicable) from Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, September 13, 2018 or such other date as notified by the Company in the newspapers.

Refund cheque(s) for wholly successful applicants using **WHITE** or **YELLOW** Application Forms, which are either not available for personal collection or which are available but are not collected in person, are expected to be despatched by ordinary post to those entitled at their own risk on Thursday, September 13, 2018. No interest will be paid thereon.

For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through a single bank account, refund monies (if any) will be despatched to their application payment bank account in the form of e-Auto Refund payment instructions. For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through multiple bank accounts, refund monies (if any) will be despatched to the addresses specified on the **HK eIPO White Form** applications in the form of refund cheque(s) by ordinary post and at their own risk.

Refund monies (if any) for applicants giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker or custodian on Thursday, September 13, 2018.

OVER-ALLOTMENT OPTION

Pursuant to the International Underwriting Agreement, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company. As of the date of this announcement, the Over-allotment Option has not been exercised.

NET PROCEEDS OF THE GLOBAL OFFERING

Based on the Offer Price of HK\$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$780.6 million (subject to rounding), assuming the Over-Allotment Option is not exercised. The Company intends to apply such net proceeds for the following purposes:

- approximately 39% of the net proceeds, or HK\$304.4 million, will be used for completing the Phase III trials of Dorzagliatin, for both monotherapy and combination trials with metformin;
- approximately 9% of the net proceeds, or HK\$70.3 million, will be used for further research and development involving Dorzagliatin, which will include combination trials;

- approximately 27% of the net proceeds, or HK\$210.8 million, will be used for the launch and commercialization of Dorzagliatin in China, including marketing, sales and manufacturing;
- approximately 11% of the net proceeds, or HK\$85.9 million, will be used for further research on mGLUR5, fixed dose combinations involving Dorzagliatin and personalized diabetes studies;
- approximately 4% of the net proceeds, or HK\$31.2 million, will be used for exploring additional licensing and partnership opportunities directly relating to diabetes or new therapeutic areas for which we believe there is a significant unmet medical need; and
- approximately 10% of the net proceeds, or HK\$78.1 million, will be used for our general corporate and working capital purposes.

For details of the use of proceeds, see “Future Plans and Use of Proceeds” in the Prospectus.

PUBLIC FLOAT

The Directors of the Company confirm that the market capitalization of the number of Shares to be held by the public will satisfy the minimum requirement prescribed under Rule 18A.07 of the Listing Rules. The Directors of the Company confirm that the three largest public shareholders of the Company do not hold more than 50% of the Shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules that a portion of the total number of the Shares with a market capitalisation of at least HK\$375 million are held by the public at the time of the Listing.. The Directors of the Company confirm that there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

Investor should be aware that the concentration of the Shareholders may affect the liquidity of the Shares. Consequently, Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

COMMENCEMENT OF DEALINGS IN SHARES

The Company will not issue any temporary documents of title in respect of the Hong Kong Offer Shares. No receipt will be issued for application monies received.

Share certificates issued in respect of the Hong Kong Offer Shares will only become valid certificates of title at 8:00 a.m. on Friday, September 14, 2018 provided that the

Global Offering has become unconditional in all respects and the right of termination as described in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination” in the Prospectus has not been exercised.

Assuming that the Global Offering becomes unconditional in all aspects at 8:00 a.m. on Friday, September 14, 2018, dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, September 14, 2018. Shares will be traded in board lots of 500 Shares. The stock code of the Shares is 2552.

By order of the Board of Directors
HUA MEDICINE

Dr. Li Chen

Chief Executive Officer and Executive Director

Hong Kong, September 13, 2018

*As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.**

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese).

* *The appointment of Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors will take effect on the Listing Date.*